Cystic fibrosis (CF)
185 results
1 - 100
Continuous glucose monitoring systems for monitoring cystic fibrosis‐related diabetes- Bisphosphonates for osteoporosis in people with cystic fibrosis
- Insulin and oral agents for managing cystic fibrosis‐related diabetes
- Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis
- Medical interventions for chronic rhinosinusitis in cystic fibrosis
- Inhaled corticosteroids for cystic fibrosis
- Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis
- Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis
- Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis
- Singing as an adjunct therapy for children and adults with cystic fibrosis
- Prebiotics for people with cystic fibrosis
- Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis
- Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
- Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis
- Oxygen therapy for cystic fibrosis: Cochrane systematic review
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis
- Treatment for chronic methicillin‐sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis
- Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation
- Sodium channel blockers for cystic fibrosis: Cochrane systematic review
- Oral calorie supplements for cystic fibrosis
- Drug therapies for reducing gastric acidity in people with cystic fibrosis
- Inhaled bronchodilators for cystic fibrosis: Cochrane systematic review
- Interventions for promoting participation in shared decision‐making for children and adolescents with cystic fibrosis
- Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis
- Bronchoscopy‐guided antimicrobial therapy for cystic fibrosis
- Omega‐3 fatty acid supplementation for cystic fibrosis
- Pneumococcal vaccines for cystic fibrosis
- Newborn screening for cystic fibrosis: Cochrane systematic review
- Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis
- Vitamin K supplementation for cystic fibrosis
- Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
- Recombinant growth hormone therapy for cystic fibrosis in children and young adults
- Digital technology for early identification of exacerbations in people with cystic fibrosis
- Vaccines for preventing influenza in people with cystic fibrosis
- Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis
- Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
- Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis
- Vitamin E supplementation in people with cystic fibrosis
- Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis
- Respiratory muscle training for cystic fibrosis
- Prophylactic anti‐staphylococcal antibiotics for cystic fibrosis
- Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis
- Totally implantable vascular access devices for cystic fibrosis: Cochrane systematic review
- Active cycle of breathing technique for cystic fibrosis
- Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis
- Antioxidant supplementation for lung disease in cystic fibrosis
- Interventions for preventing and managing advanced liver disease in cystic fibrosis
- Anti‐inflammatory drugs and analgesics for managing symptoms in people with cystic fibrosis‐related arthritis
- Palliative drug treatments for breathlessness in cystic fibrosis
- Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
- Antibiotic treatment for non‐tuberculous mycobacteria lung infection in people with cystic fibrosis
- Surgery for nasal polyposis in cystic fibrosis
- Chemical pleurodesis versus surgical intervention for persistent and recurrent pneumothoraces in cystic fibrosis
- Topical nasal steroids for treating nasal polyposis in people with cystic fibrosis: Cochrane systematic review
- Inhaled mannitol for cystic fibrosis
- Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis
- Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis
- Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
- Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis
- Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
- Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis‐related lung disease
- Oral anti‐pseudomonal antibiotics for cystic fibrosis
- Ursodeoxycholic acid for cystic fibrosis‐related liver disease
- Probiotics for people with cystic fibrosis
- Pancreatic enzyme replacement therapy for people with cystic fibrosis
- Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis
- Physical therapies for postural abnormalities in people with cystic fibrosis
- Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis
- Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis
- Macrolide antibiotics (including azithromycin) for cystic fibrosis
- Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis
- Oral steroids for long‐term use in cystic fibrosis
- Long‐acting inhaled bronchodilators for cystic fibrosis
- Short‐acting inhaled bronchodilators for cystic fibrosis
- Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis